KRAS and non-small cell lung carcinoma: The key revelation from this pooled analysis is that patients with KRAS-mutated NSCLC, including the specific G12C mutation, appear to derive substantial benefit from first-line chemo-ICI, comparable to those with KRAS wild-type NSCLC.